Literature DB >> 9759933

Antitumor activity of bax and p53 naked gene transfer in lung cancer: in vitro and in vivo analysis.

J L Coll1, A Negoescu, N Louis, L Sachs, C Tenaud, V Girardot, B Demeinex, E Brambilla, C Brambilla, M Favrot.   

Abstract

In vitro and in vivo data have demonstrated that virus-mediated p53 gene transfer can induce active cell death and lung tumor regression. In contrast, the therapeutic potential of bax, another apoptosis-inducing gene, has not been described. We compared p53 and bax cytotoxic effects by transient transfection of an average of 25 +/- 5% of the H-322 and H-358 bronchioloalveolar carcinoma cell lines in vitro. Under these conditions, bax expression killed 70 to 90% of the transfected cells whereas p53 killed only 40% of them. The killing activity of both genes involved apoptosis, as shown by TUNEL staining. Surprisingly, BrdU incorporation indicated that the cells that did resist Bax toxicity were blocked in the pre-S phase of the cell cycle, a result expected for p53 only. In vivo, repeated injections of naked DNA encoding Bax or p53 inhibited the growth of 4-mm preestablished H-322 tumors in nude mice. Growth retardation only, and not inhibition, was observed in H-358, a poorly transfectable and rapidly growing tumor. These results indicate that Bax and p53 share a similar, strong antitumor activity in vivo, even if the former is a more potent inducer of apoptosis in vitro.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759933     DOI: 10.1089/hum.1998.9.14-2063

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  2 in total

1.  Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax.

Authors:  H Garg; R Salcedo; G Trinchieri; R Blumenthal
Journal:  Cancer Gene Ther       Date:  2009-10-09       Impact factor: 5.987

2.  BAK overexpression mediates p53-independent apoptosis inducing effects on human gastric cancer cells.

Authors:  Qiang-Song Tong; Li-Duan Zheng; Liang Wang; Jun Liu; Wei Qian
Journal:  BMC Cancer       Date:  2004-07-12       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.